Clinical Stage Cell Therapy Company developing autologous and allogeneic therapies for solid tumors. • Recruited by investor B Capital to lead strategic partnering as well as future financing and IPO efforts.

Protein-protein interaction and protein degrader platform company. Advisory role on business development and financing activities, including foundational deal with BMS.

Consultancy serving private and public companies on strategic and operational issues. Examples include: • Built clean tech company through strategic financing which developed renewables from plant waste.• Built and syndicated $18M seed round with multiple strategics for protein-protein interaction start-up.• As acting CBO, spun-out key NASH asset of public therapeutics company, now Madrigal (NASDAQ; MDGL).• Sold Cellgate, Inc., a clinical oncology company, to Progen (NASDAQ: PGLA).• Hired by KPCB and TPG to start and build two diagnostic companies: Nodality, Inc., and Hx Diagnostics, Inc.

Oncolytic Virus Company developing modified myxoma virus for solid and liquid tumor applications. • Recruited by investor B Capital to lead strategic partnering as well as future financing and IPO efforts.

Innovative lncRNA company focused on targeting the dark genome, with the lead program in cardiac fibrosis. • Served as Executive Chair and Director, providing senior advice to first-time scientific management team. • Successfully raised $25M seed funding and established US operations.

Targeted Protein Degradation Company turn-around, repositioned company and raised $100M. • Repositioned company as a leader in the protein degradation space.• Raised $100M crossover round with recognized biotech investors.• Hired key management including CFO and CMO, drafted S-1, executed org process.

Early stage drug development company working on PADS and other drug targets.

Company developing exosome therapeutics.

Oncology and fibrotic disease R&D company that generated two de novo clinical programs. Executed transformational partnering deal, built company and accomplished exits for financial investor. • Negotiated build-to-buy deal with Celgene that raised an initial non-dilutive $50M in funding.• Subsequently negotiated an extension and secured additional non-dilutive funds from Celgene.• Led the company to meet key scientific and clinical milestones, timelines, and budgets.• Managed complex, multi-banker valuation process for Celgene purchase option.• Sold key asset to Blade Therapeutics via a spin-out (ATXCo), which led to successful sale of Pharmakea to Galecto Biotech (NASDAQ: GLTO) end-of-year 2019.

Spin-out from PharmAkea developing a small molecule Autotaxin inhibitor for treating fibrosis. Sold to Blade Therapeutics.

The company was focused on the application of biocataylsis for chemical production, including value added chemical manufacture and utilization of renewable feedstocks (cleantech). Funded by Monsanto.

Anti-viral therapeutics company that generated the cure for Hepatitis-C. Identified and helped hire CEO, catalyzed first major financing, and joined as a director. Initially mentored CEO and remained active in company and its operations from initial Roche deal through IPO / public listing and ultimate sale to Gilead (NASDAQ: GILD) for $11B in 2012.• Identified and helped hire CEO and catalyzed first major financing.• Negotiated and structured initial transformative $168+M plus royalty deal with Roche.• Minimized dilution through strategic funding strategies and institutional investor relations.• Chaired Nomination & Governance while company was private, Chair Audit & Compensation while public.• Helped negotiate largest Phase 2 valuation in history of industry when sold company to Gilead for $11B.

Asked to join Board after selling CellGate to Progen (NASDAQ:PGLA)

Led founding team of this Kleiner Perkins diagnostic company.

Led founding team of this Kleiner Perkins and TPG diagnostic company.

Venture backed (MPM, AIG, CIBC) clinical stage respiratory and dermatological therapeutic company developing alpha-1 antitrypsin recombinant replacement therapy. • Raised $27M in funding and ran Phase 2 trials, including inhaled alpha-1 antitrypsin for emphysema.• Hired key clinical, regulatory and business professionals to senior management team. • Conducted in major in and out-licensing activities in US, Japan and Europe for clinical assets. • Secured manufacturing at leading CMO and built GMP manufacturing facilities.

Venture backed (BCC, Venrock, ProQuest) pioneering therapeutic antibody, ADC and genomics company focused on oncology and immunology. Repositioned company and sold it to Protein Design Labs (NASDAQ: PDLI). • Renegotiated three partnerships, including refreshed $200M Biogen deal.• Launched therapeutic alliance campaigns in oncology, with NVTS term sheet resulting in successful equity sale of the company to Protein Design Labs.

Venture backed (KPCB, IVP, Mayfield) pioneering genomics and bioinformatics start-up. Hired as VP of Marketing and Business Development, promoted to President & COO after 5 months and built global operations of 200 employees. Sold company in part to Merck (NYSE: MRK) and Hitachi (NYSE: HIT). Experience included:• Raised $45M within 12 months of joining company. • Expanded business model to include both traditional and cloud-based data and software businesses. • Closed over 25 deals including major Merck project and produced several M&A term sheets.• Prepared company for IPO, including S1 and road show materials.

Global management consultancy. Youngest elected partner, managed the firm’s west coast health care practice with key relationship role at several multi-national pharmaceutical clients. Managed recruiting, hiring and training in San Francisco office. Co-authored articles on pharmaceutical and chemical industries. • Built Oncology and CNS roadmaps for a multi-national pharmaceutical company.• Identified M&A opportunities for a major pharmaceutical company, leading to the merger of two top-ten pharmaceutical companies.• Redesigned client’s scale up and manufacturing processes on two continents to support increased scale. Results catalyzed major research alliance.

Supported senior economic policy makers and Chairman Greenspan with financial market analysis for domestic interest rate policies. Participated in daily open market operations of central bank and supported Federal Open Market Committee (FOMC). Tenure included crash of ’87. Research was published in The Journal of Finance.